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E-mail address: snijman@cemm.oeaw.ac.atSynthetic lethality occurs when the simultaneous perturbation of two genes results in cellular or
organismal death. Synthetic lethality also occurs between genes and small molecules, and can be
used to elucidate the mechanism of action of drugs. This area has recently attracted attention
because of the prospect of a new generation of anti-cancer drugs. Based on studies ranging from
yeast to human cells, this review provides an overview of the general principles that underlie syn-
thetic lethality and relates them to its utility for identifying gene function, drug action and cancer
therapy. It also identiﬁes the latest strategies for the large-scale mapping of synthetic lethalities in
human cells which bring us closer to the generation of comprehensive human genetic interaction
maps.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Synthetic lethality was ﬁrst described by the American geneti-
cist Calvin Bridges in the early 20th century [1]. He noted that
when crossing fruit ﬂies (Drosophila melanogaster), certain non-
allelic genes were lethal only in combination even though the
homozygous parents were perfectly viable. The term ‘‘synthetic
lethality’’ was coined some 20 years later by his colleague Theo-
dore Dobzhansky who observed the same phenomenon in Dro-
sophila pseudoobscura [2]. Indeed, synthetic is used here for its
ancient Greek meaning: the combination of two entities to form
something new.
Synthetic lethality is thus deﬁned as a type of genetic interac-
tion where the co-occurrence of two genetic events results in
organismal or cellular death (Fig. 1) [3,4]. Similarly, genetic combi-
nations that yield a non-lethal growth impairment are called syn-
thetic sick but are usually grouped together with synthetic lethal
interactions, as is done in this review. Although best known in
the context of loss-of-function mutants, combinations of other
types of perturbations can also result in synthetic lethality, includ-
ing overexpression of genes, the action of a chemical compound or
environmental change [5–8].
Geneticists have been interested in synthetic lethal interactions
because they reveal information about the functional relationships
between genes and are relatively easy to score in genetic screens
[9]. In addition, as many basic cellular processes are ultimately re-
quired for viability, synthetic lethality screens can be used to studyal Societies. Published by Elseviera wide range of processes. In recent years, synthetic lethality has
attracted attention from cancer biologists as it provides a new an-
gle for therapy and may explain the sensitivity of cancer cells to
certain drugs [7,10]. This review intends to provide the conceptual
framework and utilities of synthetic lethality and highlights the
main strategies to identify them in human cells using functional
genetics.
2. The principles underlying synthetic lethality involve
robustness and buffering
Synthetic lethal genetic interactions exist because of the mech-
anisms employed by cells and organisms to maintain homeostasis
in the face of diverse genetic and environmental challenges [4,11].
This robustness of cells and organisms is thought to play a critical
role in evolution, developmental canalization (i.e., the ability to
produce the same phenotype regardless of genotype) and multifac-
torial diseases such as cancer [12,13]. Genetically, robustness is
highlighted by the fact that while 80% of budding yeast (Saccha-
romyces cerevisiae) genes are not required for proliferation in rich
medium [14], most single mutants are sensitive for an additional
perturbation (i.e., a synthetic lethal interaction) such as knockout
of a second gene, a change in culture conditions or exposure to a
chemical compound [8,15]. Thus synthetic lethality can be thought
of as a feature of genetic robustness.
Genetic robustness is established via various buffering mecha-
nisms, such as functional redundancy and proteins known as
capacitors. In diploid organisms, redundancy is the simplest type
of buffering due to the presence of two alleles in the genome.
Indeed, many heterozygous knockout mice are not discernableB.V. Open access under CC BY-NC-ND license.
Fig. 1. Schematic representation of synthetic lethality. Two genes are synthetic lethal only when their simultaneous inactivation results in cellular or organismal death. In
this example, deletion of either gene A or gene B does not affect viability whereas inactivation of both at the same time is lethal.
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genes that have a common ancestor and can still partially perform
the same task (e.g., AKT1 and AKT2), although in yeast this type of
redundancy is relatively rare, explaining only a small fraction of
genetic interactions [15]. Instead, robustness is mostly provided
by non-homologous genes operating in the same cellular process
or in back-up pathways (Fig. 2). For example, a large scale RNA
interference (RNAi) screen to identify human genes that were syn-
thetic lethal with low concentrations of the mitotic inhibitor pac-
litaxel found some coding for proteins of the mitotic spindle
apparatus itself as well as others coding for proteins of the protea-
some, which is involved in protein-degradation, indicating that
mitosis is buffered at several different levels [16].
Another interesting type of buffering is provided by so-called
‘‘capacitors’’ like heat shock proteins and chromatin regulators that
can mask the effects of many different mutations (Fig. 2)
[15,17,18]. Therefore, capacitors display many synthetic lethal
interactions. The role of heat shock proteins in the buffering of ge-
netic variations is believed to stem from their ability to promote
proper folding of mutated proteins. Capacitors may also explain
the effectiveness of HSP90 and histone deacetylase inhibitors as
anticancer drugs, a topic that is discussed below [19].
Thus, cellular systems maintain homeostasis partly by ensuring
that processes do not depend on any single component, which
could easily be perturbed by mutation or environmental effects,
setting the scene for synthetic lethal interactions [4,11,13].Fig. 2. Cartoon of a hypothetical synthetic interaction network. Genes are repre-
sented by blue, red and purple circles and their synthetic lethal interactors
(buffering connections) indicated by red lines. Two processes (e.g., DNA repair and
DNA replication) are buffered such that many single genes within each process are
not essential (circles connected by red lines). Some genes are extrinsically buffered
across two different processes whereas others are buffered by independent
capacitator genes.3. Synthetic lethality provides insights into gene function and
drug action
The true potential of synthetic lethality has been most exten-
sively realized in yeast [9]. Here, the large-scale quantitative map-
ping of synthetic lethal interactions has reached genome-wide
scale and the resulting comprehensive genetic interaction net-
works are a rich source for the functional annotation of genes
[8,15]. This is because genes that act in the same process often buf-
fer each other, so they also tend to cluster together in these net-
works and gene function or even enzyme–substrate relationships
can be inferred [3,20]. Clearly, the elucidation of similar compre-
hensive synthetic lethal interaction networks in human cells
would be very attractive, particularly as the majority of genes have
still not been assigned a function a decade after the ﬁrst draft of the
human genome was generated.
Drugs also display synthetic lethal interactions with genes,
which can be used to study their effects on cells [6]. Indeed,
drug-gene interaction screens in yeast have been used extensively
to study the mechanism of action of drugs and similar studies in
human cells would be invaluable [21–24]. This is particularly
important because for many drugs that are used in the clinic not
all protein targets are known, which is essential for understanding
their unwanted side effects.
Knowledge of drug–gene synthetic lethal interactions may also
be used to design combination therapies and predict synergistic/
sensitizer drugs [16,25–28]. This is particularly important in cancer
and infectious diseases, as drug combinations with distinct cellular
targets can limit treatment resistance and synergistic drugs can be
used at much lower concentrations to achieve the same biological
effect, thereby limiting side effects [29].
4. Synthetic lethality provides a framework for the mechanism
of action of chemotherapy
The notion that conventional chemotherapeutics work by tar-
geting fast dividing cells is not the whole story and a molecular
understanding of why certain cancer cells respond to a speciﬁc
chemotherapeutic while others are resistant, remains largely unex-
plained [7]. It is also not apparent why some cancers are sensitive
for drugs such as Bortezomib, Vorinostat and Geldanamycin that
inhibit the proteasome, histone deacetylases and HSP90 respec-
tively, since these cellular targets are not directly implicated in
tumorigenesis. Instead the effectiveness of these chemotherapies
may be due to synthetic lethality [5,7]. For example, given that
genomic instability, defective DNA repair, and deregulated tran-
scription are some of the hallmarks of cancer, drugs that further
perturb these processes may be speciﬁcally toxic (i.e., synthetically
lethal) in cancer cells. In other words, the molecular changes in the
cancer cells have strained the buffering capacity of these systems.
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cancer types and individual tumors, particularly a map of the syn-
thetic interactions between DNA repair pathways and DNA dam-
age-based cancer therapies, would be an invaluable aid for guiding
therapy choice.5. Synthetic lethality and new opportunities for cancer
therapeutics
Although much is now known about the large number of molec-
ular aberrations that are found in cancer it can be difﬁcult to di-
rectly translate this knowledge into new therapies. A major
hurdle in drug discovery is that most oncogenes are not easily
accessible for inhibition by small molecules and the restoration
of loss-of-function changes in tumor suppressor genes in patients
is nearly impossible [5]. In their seminal paper, Lee Hartwell and
Stephen Friend proposed that synthetic lethality may provide a
solution [30]. They reasoned as follows: Cancer cells have acquired
molecular changes that distinguish them from their wild-type
counterparts. Consequently, cancer cells have been ‘‘re-wired’’,
exposing new genetic vulnerabilities. Synthetic lethal interaction
partners of cancer-associated molecular changes should therefore
offer excellent therapeutic opportunities.
This notion is somewhat related to oncogene addiction, the
observation that tumorigenesis cells become ‘‘addicted’’ to their
genetic changes and thus vulnerable for the sudden inactivation
of oncogenes or reactivation of tumor suppressors [31]. To discrim-
inate between synthetic lethal interactions and oncogene addic-
tion, the former has therefore also been called ‘‘non-oncogene
addiction’’ [7].
The great potential of synthetic lethality-based cancer therapy
is best illustrated by a landmark achievement concerning the
tumor suppressor and DNA repair genes BRCA1 and BRCA2, muta-
tions in which can cause breast and ovarian cancer. The BRCA
genes display synthetic lethality with another DNA repair enzyme
called PARP and the tumors of patients carrying these mutations
could be successfully treated using a chemical PARP inhibitor with
remarkably mild side effects [32–35]. Interestingly, recent studies
have suggested various other synthetic lethal partners of PARP,
including the tumor suppressor PTEN [28,36–38].
The BRCA/PARP case has become the paradigm for a new class
of rational cancer therapies based on the synthetic lethality con-
cept [39–41]. Furthermore, it calls for a comprehensive effort to
identify synthetic lethalities in human cells and the challenge
now remains to adapt newly-available methods to identify them.6. In silico prediction and evolutionary conservation of
synthetic lethality
Based on yeast studies it is known that some characteristics
make two genes more likely to display a genetic interaction. For in-
stance, shared localization, physical interaction and co-expression
are some of the predictors of synthetic lethality [42]. But even with
the high-quality data from yeast, prediction algorithms are unreli-
able, and empirical testing remains the only way to conﬁdently and
comprehensively identify genetic interactions [9].
As a large number of yeast genes have human orthologs, and
genome scale genetic networks are available in yeast, it is interest-
ing to explore the evolutionary conservation of genetic interac-
tions. Remarkably, S. cerevisiae and Saccharomyces pombe, yeast
species that diverged 300–600 million years ago and differ in many
biological properties, share approximately 30% of their genetic
interactions, suggesting signiﬁcant conservation [43,44].
The utility of yeast for the accurate prediction of synthetic
lethality in higher eukaryotes remains unclear. Although a studyof spindle assembly checkpoint genes found that about 25% of
yeast synthetic lethalities were conserved in the nematode Caenor-
habdites elegans [45], several larger-scale studies found as few as
1% of interactions conserved between these two organisms, ques-
tioning the general conservation of synthetic lethality [46,47].
Some of the weak conservation may be explained by technical lim-
itations or perhaps genetic interactions are more likely to be con-
served only in certain biological processes such as chromosome
segregation. Indeed, the few studies that have successfully used
yeast genetic interactions to predict interactions in mammalian
cells suggest there is limited conservation [23,48–50]. Future stud-
ies will undoubtedly shed more light on this important question
but in the meantime, the only way to systematically identify syn-
thetic lethalities in higher eukaryotes, including humans, is to use
an empirical approach.7. Synthetic lethality screen approaches in human cells
Until recently, synthetic lethality screens were mostly limited
to screens using chemical compounds but a scalable approach to
identify gene-gene interactions was lacking [27,51,52]. With the
discovery of RNAi it has become feasible to systematically identify
synthetic lethal interactions in human cells, and a variety of differ-
ent screening strategies have recently been developed.
The two general approaches in classical genetics that are used
to link phenotype with genotype (referred to as forward and
reverse) can also be used to classify synthetic lethality screens in
human cells (Fig. 3). Traditional forward genetics starts with a
phenotype of interest, for instance obtained by screening a collec-
tion of mutants, and aims to identify the responsible gene. Con-
versely, reverse genetics takes a deﬁned mutant, for example a
knockout mouse, and looks for the functional consequence of this
genetic change. In synthetic lethality screens, the forward ap-
proach uses the genetic variability in a collection of cancer cell
lines whereas in the reverse tactic a single speciﬁc genetic change
is engineered resulting in an isogenic cell line pair. In both cases
the next step is to identify genes that are required for cell viability
using RNAi-mediated knockdown and linking these to the geno-
typic differences.
Both approaches have been successfully employed but have
strengths and weaknesses. A caveat of the forward approach is that
cell lines typically show a plethora of heterogeneous aberrations,
making it challenging to correlate speciﬁc genetic changes with
the identiﬁed sensitivity to a certain knockdown. Reverse genetic
approaches have the advantage that every sensitivity is most likely
a true genetic interaction. However, as the isogenic cell line was
artiﬁcially created the genetic background and cellular state does
not strictly reﬂect a ‘‘normal’’ cancer cell. Therefore, the genetic
interactions do not necessarily mirror those in cancer cells that
naturally harbor the genetic defect.
A second methodological distinction is based on the screening
format. To circumvent the practical limitations of screening indi-
vidual short hairpin (shRNA) vectors in a single-well, several
groups have developed pooled methods that are inspired by tech-
nologies pioneered in yeast to genetically barcode knockout clones
so they can still be accurately identiﬁed even within a mixed pop-
ulation of cells [53–56]. Such screens are much easier to handle
than large-scale single well screens and thus have a higher
throughput (Fig. 4).8. Examples of synthetic lethality screens
In the last year, several RNAi screening approaches were re-
ported used to identify synthetic lethal interactions with oncogenic
RAS, which is frequently mutated in a variety of cancers but difﬁcult
Fig. 3. Forward screen approach to identify synthetic lethality. Cell lines (A–H) are grouped based on mutant status of a single gene (X). Essential genes that are common in
the mutants but not in the wild type cell lines are potential synthetic lethal (SL) interactions with gene X and are selected for validation in an independent panel of cell lines.
Fig. 4. Overview of a pooled shRNA screen set-up. Cell lines (A and B) are infected with short hairpin RNA libraries targeting thousands of gene products by RNAi. Cells are
cultured to allow the depletion of those containing shRNAs that target essential genes. Genomic DNA is isolated and the vectors are quantiﬁed using so-called barcode
sequences (short stretches of DNA) that are unique for each shRNA vector. By comparing the genes that are required in one cell line but not the other by custom micro-array
or deep sequencing, potential synthetic interactions can be identiﬁed.
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attractive for a synthetic lethal therapy. As well as being some of
the most comprehensive human synthetic lethality screens to date,
these studies also effectively highlight the different screening
approaches that are currently available. In addition, they offer an
opportunity to discuss some of the current limitations and chal-
lenges of synthetic lethality screens in human cells.
In two papers published by the groups of William Hahn and
Gary Gilliland, a forward, single-well single-gene approach was
employed [57,58]. In the larger of the two screens, kinases, phos-
phatases and known cancer-relevant genes (1000 in total) were
inhibited by RNAi in a panel of 19 RAS mutant and wild type cell
lines [58]. ShRNAs were selected by supervised clustering forfollow-up experiments and the hits after a second round of validation
in a panel of lung cancer cell lines were RAS itself and the NF-jB
activator TBK1, which is consistent with previously reported obser-
vations that RAS transformed cells require active NF-jB signaling
and that RAS activates TBK1 [59,60]. In addition, the therapeutic
potential of targeting the newly identiﬁed synthetic lethal interac-
tion between the NF-kappa B pathway and oncogenic RAS was
demonstrated in a mouse model of lung cancer [61].
In another study, Stephen Elledge and colleagues undertook an
alternative reverse pooled approach to identify synthetic lethal
RAS interactors [62]. Using a clone of the DLD1 colorectal cancer
cell line differing only in the mutational status of RAS, a so-called
isogenic clone, they screened almost 75 000 shRNA vectors (covering
Fig. 5. The synthetic lethality window. In both examples the mutant cells (purple lines) display a genetic interaction with a second gene that is progressively inhibited (x-
axis). However, in the upper graph the synthetic lethality window is limited, as the wild type cells are also affected before viability is completely inhibited in the mutant cells
(red line). In contrast, the lower graph shows that full inhibition of viability can be achieved in mutant cells without affecting the wild type cells.
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ties (Fig. 4). Interestingly, the putative RAS synthetic lethal interac-
tors that were identiﬁed are involved in diverse processes
including proteasome function, suggesting that RAS-induced trans-
formation requires substantial buffering. In particular, the authors
found that RAS mutant cells are hypersensitive to inhibition of the
mitosis checkpoint protein PLK1. In a similar effort, the laboratory
of Julian Downward recently performed a screen in isogenic colo-
rectal carcinoma HCT116 cells with a pooled library targeting
2500 genes and identiﬁed the transcription factor SNAIL2 to be
required only in RAS mutant cells [63].9. Limitations of RNAi screens and outlook
The overlap between the synthetic lethalities in the mentioned
RAS synthetic lethality screens is very limited. Some of this may
be due to the use of different cell lines for the screens and technical
approach but given that 75% of the interactions identiﬁed in the
genome-wide DLD1 screen also displayed an effect in HCT116 cells
this is unlikely to be the complete explanation [62]. Rather, the use
of different shRNA libraries that target only partially overlapping
genes and inhibit gene expression with different efﬁciencies,
provides a technical explanation and indicates a large number of
false-negatives in the screens. Indeed, the variability in knockdown
efﬁciency and the fact that RNAi typically only results in 70–90%
inhibition of expression highlights a weakness of this tool. In addi-
tion, the fact that RNAi screens are plagued with off target effects
provides an explanation for false positives. Therefore, the availability
and further development of powerful screening technologies, includ-
ing better characterized knockdown libraries, will continue to be a
driving force behind human functional genetics. Particularly, new
technologies such as a method for the large-scale generation of
human knockout cells will add to the current tool-box and may
ﬁnally provide yeast-like genetics in human cells [64].
Although the mentioned new and other known synthetic lethal
interactions may provide handles for novel therapies, most of the
described genetic interactions in cancer cells do not strictly adhere
to the deﬁnition of synthetic lethality which demands that only the
combination of two perturbations results in lethality. Frequently
the perturbations are also toxic on their own, which would limit
the speciﬁcity of the drug and likely introduce unwanted side-ef-
fects, or the interaction is more accurately described as synthetic
sick so the cancer cells would not be completely eliminated.Analogous to the therapeutic window for drugs, i.e., the safe and
effective dose range, ‘‘the synthetic lethality window’’ of the genet-
ic interaction will be important for its potential as a therapy
(Fig. 5). For example, with the BRCA-PARP synthetic lethal interac-
tion, BRCA mutant cells are some two orders of magnitude more
sensitive to PARP inhibitors than non-mutant cells and this strong
responsiveness is probably key to its clinical success. It is currently
unclear how common this type of strong genetic interaction is in
human cells.
In summary, synthetic lethality is a valuable concept to under-
stand the functions of genes, the mechanism of action of drugs and
their interactions, and has immediate relevance for cancer therapy.
In recent years it has brought inspiration to search for a new class
of anti-cancer therapies and future treatment strategies will
increasingly consist of combination therapies based on personal-
ized tumor vulnerabilities, including synthetic lethality. Aided by
powerful genetic tools, there is little doubt that we are at the brink
of an explosion of synthetic lethality information in human cells.
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